Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)

Patients will be treated with immunoadsorption on 4 consecutive days week 1 and three consecutive days week 5 and week 9.

The clinical improvement and histological and serological tests will be evaluated.

Inclusion criteria

• Adults (> 18 year) with severe atopic dermatitis (objective SCORAD > 40)
• Who's AD is persistent and stable since more than 1 year
• Who signed the informed consent
• Who are not pregnant or do not plan to become pregnant, during the immunoadsorption treatment
• Who were treated in the recent past with phototherapy or immunosuppressive therapy ( one or more : cyclosporin A, methotrexate , azathioprine , mycophenolate , systemic corticosteroids ) and where this therapy was not sufficiently helpful, had unacceptable side effects or are contraindicated

Exclusion criteria

• Patients who did not give an informed consent.
• Patients with mild or moderate AD.
• Patients with severe AD improving with, and tolerating, standard therapy (including phototherapy, short periods of corticosteroids, the above mentioned immunosuppressive therapies ) and having no contra-indications for these therapies
• Pregnant women and female patients willing to become pregnant during the planned period of treatment or immediately after.
• Having contra-indications for immunoadsorption:

• Patients with a known allergy for the material used during immunoadsorption.
• Severe cardiovascular diseases.
• Severe bleeding during anticoagulation .
• Treated with ACE-inhibitors.
• Patients younger than18 years.
• Having a malignant disease not under remission